Top Globe News – Lifestyle
Author:
Pentixapharm Holding AG
Pentixapharm Announces IND Submission to FDA for Phase 3 PANDA Study of First-in-Class CXCR4-Targeted Cardiovascular Diagnostic
May 11, 2026